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The mechanistic target of rapamycin (mTOR) is emerging as playing a central role in
regulating T cell activation, differentiation, and function. mTOR integrates diverse signals
from the immune microenvironment to shape the outcome of T cell receptor (TCR) antigen
recognition. Phosphatidylinositol 3-kinase (PI3K) enzymes are critical mediators of T cell
activation through their generation of the second messenger phosphatidylinositol (3,4,5)
triphosphate (PIP3). Indeed, PIP3 generation results in the activation of Protein Kinase B
(PKB, also known as AKT), a key activator of mTOR. However, recent genetic studies have
demonstrated inconsistencies between PI3K disruption and loss of mTOR expression with
regard to the regulation of effector and regulatory T cell homeostasis and function. In this
review, we focus on how PI3K activation directs mature CD4 T cell activation and effector
function by pathways dependent on and independent of mTOR signaling. Importantly,
what has become clear is that targeting both mTOR-dependent and mTOR-independent
PI3K-induced signaling distally affords the opportunity for more selective regulation of
T cell differentiation and function.
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INTRODUCTION
The Class IA phosphatidylinositol 3-kinase (PI3K) family con-
sists of a heterodimeric complex of one of the 110-kDa catalytic
subunits (p110α, β, δ) with a regulatory subunit (p85α, p55α,
p50α, p85β, and p55γ), reviewed in Kane and Weiss (2003);
Okkenhaug and Vanhaesebroeck (2003). Catalytic subunits are
each encoded by separate genes, while the pik3r1 gene generates
p85α, p55α, and p50α from alternative promoters and the pik3r2
and pik3r3 genes encode p85β and p55γ, respectively. Details
of receptor interactions with PI3Ks have recently been reviewed
elsewhere (Okkenhaug and Fruman, 2010). Co-localization of
catalytic subunits with regulatory subunits permits juxtaposi-
tion of catalytic subunits to the cell membrane in response to
receptor ligation, increasing the local synthesis of phosphatidyli-
nositol (3,4,5) triphosphate (PIP3). The p110α and β subunits
are ubiquitously expressed while p110δ expression is restricted to
hematopoietic cells. The Class IB PI3 Kinase family consists of
a complex of the p110γ catalytic subunit and either the p101 or
p84 regulatory subunits. This complex interacts with G-protein
coupled receptors including chemokine receptors via binding
to Gβ and γ regulatory proteins. Like p110δ, p110γ expression
is restricted to hematopoietic cells. Accumulation of the PIP3
signaling intermediate is opposed by phosphatase and tensin
homolog (PTEN) that converts PIP3 back to phosphatidylinositol
(4,5) bisphosphate and Src homology 2 domain-containing inosi-
tol phosphatase (SHIP)1 and SHIP2 that hydrolyze PIP3 to phos-
phatidylinositol (3,4) bisphosphate (Okkenhaug and Fruman,
2010).
PIP3 acts as a second messenger to mediate downstream sig-
naling by recruitment of pleckstrin homology (PH) domain con-
taining proteins that bind to the high local concentrations of PIP3
generated by PI3Ks at the inner leaflet of the plasma membrane.
Examples include the Tec family of tyrosine kinases that mediate
signals to phospholipase C-γ (PLCγ), the 3-phosphoinositide-
dependent protein kinase 1 (PDK1), and Protein Kinase B (PKB),
also known as AKT [reviewed in Kane and Weiss (2003)].
Members of the Vav family of guanine nucleotide exchange factors
that regulate cellular motility may also be recruited via PIP3 bind-
ing, although some data suggest recruitment may be indirect via
other protein interactions. AKT binding to PIP3 induces a con-
formational change that renders it accessible to phosphorylation
at residue T308 by PDK1 co-localized at the plasma membrane,
resulting in activation of AKT serine/threonine kinase activity
(Stokoe et al., 1997; Currie et al., 1999; Milburn et al., 2003).
One critical substrate for activated AKT is tuberous sclerosis com-
plex (TSC)-2. TSC2 functions with TSC1 as a GTPase activating
complex for Ras homolog enriched in brain (Rheb). TSC2 is inac-
tivated by phosphorylation, resulting in accumulation of GTP-
bound Rheb that activates the mechanistic target of rapamycin
(mTOR) that is in a complex with regulatory-associated pro-
tein of mTOR (Raptor) termed mTORC1. Activated mTORC1
phosphorylates and inhibits the eukaryotic initiation factor 4E-
binding proteins (4E-BP1, 2, 3) and activates the p70 ribosomal
S6 kinases (S6K1, 2), resulting in increased protein translation
and upregulation of glycolysis, promoting cell growth and divi-
sion [reviewed in Laplante and Sabatini (2012)]. In addition,
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mTORC1 activation is required for several key elements of T cell
effector differentiation that are discussed in further detail below.
A second mTOR complex containing the rapamycin insensi-
tive companion of TOR (Rictor) and the mammalian homolog of
the yeast SIN1 gene (mSIN1), termed mTORC2, is also critical to
mediating PI3K signaling via AKT. Although the precise mech-
anisms underlying activation of mTORC2 remain incompletely
understood, it was recently observed that physical association
with ribosomes stimulates mTORC2 activity (Zinzalla et al.,
2011) and that Rictor acetylation by p300 stimulates mTORC2
activity (Glidden et al., 2012). mTORC2 is strongly activated
in T cells by costimulation and cytokines [reviewed in Cantrell
(2002)]. mTORC2 has several substrates including serum- and
glucocorticoid-induced protein kinase 1 (SGK1), protein kinase
C-α (PKC-α), and importantly, AKT itself. Phosphorylation at
residue S473 in the AKT hydrophobic motif modifies substrate
specificity of AKT and enhances its kinase activity (Sarbassov
et al., 2005; Facchinetti et al., 2008; Garcia-Martinez and Alessi,
2008). In particular, S473 phosphorylation is required to permit
AKT to phosphorylate members of the Forkhead box family of
transcription factors Foxo1 and Foxo3a (Jacinto et al., 2006).
Foxo phosphorylation leads to the cytoplasmic retention of these
transcription factors with resulting downregulation of target gene
expression (Brownawell et al., 2001). In T cells, a key Foxo target
is KLF2 that regulates expression of CD62L, the c–c chemokine
receptor 7 (CCR7), and the sphingosine-1-phosphate receptor
(S1P1R) which each control homing of lymphocytes into and out
of secondary lymphoid tissues [reviewed in Finlay and Cantrell
(2010)].
The signaling cascade from receptors through PI3K to mTOR
described above appears to imply a linear relationship, and older
studies utilizing small molecule inhibitors of either PI3Ks such
as wortmannin or LY294002 or mTOR using rapamycin demon-
strated similar profound inhibition of T cell function in vitro (Kay
et al., 1991; Ward et al., 1995). However, recent analysis of the
pathways usingmore specific inhibitors and genetic manipulation
has identified a more complex signaling cascade with both over-
lapping and unique functions. Phenotypes of mice discussed in
this review with targeted disruption of components of the PI3K
or mTOR pathways are summarized in Table 1 below.
INTERRUPTION OF THE PI3K/AKT/mTOR PATHWAY AT
DIFFERENT LEVELS HAS DIFFERENTIAL EFFECTS ON
T CELL ACTIVATION
A critical aspect to TCR signaling is its ability to activate PLCγ
and generate the second messenger inositol triphosphate (IP3)
that triggers Ca++ entry following activation. This Ca++ binds
calmodulin and activates calcineurin, which dephosphorylates
NF-AT transcription factors that translocate to the nucleus to
activate transcription of genes that regulate both T cell acti-
vation/effector function and tolerance (Macian et al., 2002).
Cyclosporine acts as a potent immunosuppressant by binding
to cyclophilin and blocking activation of calcineurin and thus
NF-AT. Rapamycin inhibits T cell activation by a different mecha-
nism, by binding to FKBP12 and preventing association of Raptor
and mTOR to form the mTORC1 complex. The importance of
this difference is highlighted by the fact that activation of Th1 cells
in the presence of rapamycin renders them subsequently anergic
and incapable of proliferation and IL-2 secretion upon secondary
stimulation after rapamycin is washed away, in a manner simi-
lar to Th1 cells stimulated through the T cell receptor (Signal 1)
in the absence of costimulation via CD28 (Signal 2) (Powell
et al., 1999). This occurs despite the fact that while rapamycin
acutely inhibits T cell proliferation, it does not block initial IL-2
secretion. Cyclosporine, in contrast, blocks both proliferation
and IL-2 secretion acutely but does not impair secondary stim-
ulation after drug is removed. Rapamycin appears to promote
anergy and tolerance by permitting normal TCR-mediated acti-
vation of NF-AT gene targets including the transcription factors
Egr-2 and Egr-3 and their targets such as Cbl-b, DGKα, and
Fas-L that limit T cell activation and promote apoptosis (Sanjuan
et al., 2001; Macian et al., 2002; Safford et al., 2005; Zha et al.,
2006). As these signaling pathways would predict, co-incubation
of T cells with cyclosporine and rapamycin blocks rapamycin-
induced anergy (Powell et al., 1999). That is, blocking proximal
TCR-mediated signaling with cyclosporine mitigates the effects of
blockingmTORwith rapamycin.We emphasize the consequences
of blocking proximal signaling with cyclosporine and more distal
signaling with rapamycin because a parallel can be drawn com-
paring genetic blockade of mTOR that promotes generation of
regulatory T cells (Treg) and genetic blockade of proximal PI3K
signaling that results in decreased Treg function in vivo (to be
discussed in depth below).
The generation of mice with T cell conditional deletion of
mTOR using a floxed allele crossed with a CD4-Cre transgenic
mouse confirms the specificity of rapamycin for blocking mTOR-
mediated signaling (Delgoffe et al., 2009). Stimulation of mTOR
deficient T cells with anti CD3/CD28 induces robust, even slightly
increased, proximal AKT T308 phosphorylation but it is unable
to elicit S6K1 and AKT S473 phosphorylation. Like rapamycin
treated T cells, mTOR deficient T cells show normal IL-2 secretion
during primary stimulation but reduced proliferation. However,
the consequence of activation of naïve T cells lackingmTOR is the
inhibition of effector differentiation and the generation of Tregs.
Since PI3K is upstream ofmTOR, the effect of a PI3K inhibitor
would be predicted to mimic rapamycin. In fact, stimulation of T
cells in the presence of wortmannin does acutely block prolifera-
tion, but IL-2 secretion is also inhibited, similar to cyclosporine
(Ward et al., 1995). Despite this difference, the presence of
wortmannin during T cell priming does result in anergy upon
restimulation similar in magnitude to that achieved by costimula-
tory blockade with CTLA4-Ig which blocks B7/CD28 interactions
(Taub et al., 1997). Importantly, subsequent work has demon-
strated that wortmannin is not selective for PI3K as originally
thought, but it can inhibit mTOR as well (Brunn et al., 1996),
therefore it is not clear if the findings reported by Taub et al.
merely mimic the effect of rapamycin-induced mTOR blockade.
Clarification of distinctions between PI3K and mTOR-dependent
signals has subsequently been provided by genetic analysis.
Initial work deleting individual PI3K regulatory subunits
demonstrated significant functional redundancy in T cells, with
no overt defects in T cell development and signaling after disrup-
tion of p85α and paradoxically enhanced TCR and IL-2-induced
proliferation in p85β knockouts (Fruman et al., 1999; Suzuki
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Table 1 | T cell phenotype and function in PI3K and mTOR pathway gene-targeted mice.
Gene Phenotype References
pik3r1 (p85α−/−, p55α−/−, p50α−/−) Normal T cell development and proliferation Fruman et al., 1999
pik3r1 (p85α−/−) Normal T cell development and proliferation Suzuki et al., 1999
pik3r2 (p85β−/−) Normal T cell development
Enhanced proliferation to TCR stimulation or TCR + IL-2
Deane et al., 2004
r1T/r2n (p85α−/−, p55α−/−, p50α−/−,
p85β−/−)
Normal T cell development
Normal Th1 but reduced Th2 differentiation
Impaired T-dependent antibody response
Reduced Treg numbers, spontaneous autoimmunity
Oak et al., 2006
Deane et al., 2007
pik3cd (p110δ−/−, CD4-Cre;p110δflox/flox, or
OX40-Cre;p110δflox/flox)
Normal T cell development and proliferation
Impaired T-dependent antibody response
Clayton et al., 2002
Rolf et al., 2010
pik3cd (p110δD910A/D910A ) Decreased peripheral T cell numbers
CD3/CD28-induced proliferation and IL-2 normal
Antigen-induced proliferation and IL-2 reduced
Impaired Th1 and Th2 differentiation in vitro
Reduced Th1 contact hypersensitivity
Inappropriate Th1 differentiation to Th2 stimulus in vivo
Reduced Th17 differentiation with attenuated EAE
Reduced IL-10 production
Impaired Treg function with autoimmune colitis
Impaired T-dependent antibody response
Okkenhaug et al., 2002
Okkenhaug et al., 2006
Patton et al., 2006
Nashed et al., 2007
Liu et al., 2009
Rolf et al., 2010
Soond et al., 2010
Haylock-Jacobs et al., 2011
pik3cg (p110γ−/−) Normal T cell development
Variably decreased or normal proliferation
Variably decreased or normal cytokine production
Abnormal trafficking to sites of inflammation
Impaired trafficking to chemokines
Sasaki et al., 2000
Alcazar et al., 2007
Garcon et al., 2008
Martin et al., 2008
Thomas et al., 2008
pten (Lck-Cre;PTENflox/− or
OX40-Cre;PTENflox/flox)
Lymphoproliferative disorder (Lck-Cre)
Enhanced T cell proliferation and cytokine production
Spontaneous autoimmunity (Lck-Cre)
Enhanced T cell help (OX40-Cre)
Enhanced tumor rejection (OX40-Cre)
Suzuki et al., 2001
Soond et al., 2012
frap1 (CD4-Cre;mTORflox/flox) Normal T cell development
Reduced proliferation
Normal initial IL-2 secretion
Impaired Th1, Th2, and Th17 differentiation
Spontaneous iTreg differentiation
Delgoffe et al., 2009
rheb (CD4-cre;rhebflox/flox) Normal T cell development
Impaired Th1 and Th17 differentiation
Normal Th2 and iTreg differentiation
Delgoffe et al., 2011
raptor (Lck-Cre;raptorflox/flox) Reduced peripheral T cell numbers
Impaired Th17 differentiation
Kurebayashi et al., 2012
rictor (CD4-Cre;rictorflox/flox or proximal
Lck-Cre;rictorflox/flox)
Normal T cell development
Variably decreased Th1 and Th17 differentiation
Impaired Th2 differentiation
Normal iTreg differentiation
Impaired T-dependent antibody response
Lee et al., 2010
Delgoffe et al., 2011
et al., 1999; Deane et al., 2004); therefore the p85α and p85β
knockouts were crossed to disrupt all Class IA PI3K activity.
This was accomplished by crossing pik3r12loxP/2loxP mice with
pik3r2−/− mice and breeding these onto an Lck-Cre background
to cause T cell specific deletion of both regulatory subunits
(Deane et al., 2007). Resulting mice, termed r1T/r2n, have nor-
mal generation of T cells, but such cells have profound decreases
in expression of multiple PI3K catalytic subunits with greatly
reduced p110β and undetectable p110α and p110δ. Such T cells
demonstrate expected loss of CD3/CD28-induced AKT S473
phosphorylation. This may be due to impaired mTORC2 sig-
naling but it is important to comment that recruitment of AKT
to the cell membrane to be phosphorylated by PDK1 at T308 is
predicted to be interrupted as well. Since T308 phosphorylation
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was not directly measured, it cannot formally be determined
whether the loss of AKT S473 phosphorylation represents a lack
of singly phosphorylated AKT substrate for mTORC2 or is a con-
sequence of reduced mTORC2 activity. Also, phosphorylation
of other mTORC2 substrates such as SGK1 and PKCα was not
reported in this study. Similar data on AKT S473 phosphorylation
in isolation without other measures of mTORC2 activity has been
extensively reported in other systems described in this review.
Thus, interpretation of relative levels of mTORC2 activity in some
of these systems remains speculative but is helpful to consider
when comparing phenotypes with systems where mTORC2 is
selectively disrupted. Deane et al. unexpectedly provide evidence
for preservation of some CD3/CD28-induced phosphorylation of
ribosomal S6 at S235/236. While some data have suggested that
this particular S6 phosphorylation site may be more dependent
on RSK activity than mTOR activity upstream of S6K (Salmond
et al., 2009), Deane et al. demonstrate that this S6 phosphoryla-
tion in r1T/r2n T cells is blocked by rapamycin, supporting that
in r1T/r2n T cells some mTORC1 activity is preserved. TCR-
induced calcium flux was modestly reduced in r1T/r2n T cells
and TCR-induced NF-κB activation as measured by IκB phos-
phorylation was significantly reduced, consistent with reduced
activation of the Tec kinase/PLCγ pathway due to inefficient
PIP3 generation. However, IκB phosphorylation could be nor-
malized with CD28 costimulation. This partial preservation of
CD3/CD28-induced signals including some mTOR activation
may explain why proliferation is only slightly reduced while IL-2
and IFN-γ are more profoundly suppressed, which would not be
predicted by the PI3K and rapamycin inhibitor studies described
above and differs from the phenotype following T cell specific
deletion of mTOR.
Since disruption of the regulatory subunits indirectly affects
expression of multiple PI3K catalytic subunits, targeted deletion
of individual catalytic subunits has been used to dissect how each
one contributes to T cell activation with the rationale that a selec-
tive inhibitor of a T cell dominant PI3K isoform might have
less off target effects in non-immune cells and be a more useful
immunosuppressant. Two parallel approaches have been used to
determine the role of the PI3K p110δ isoform in lymphocytes,
simple gene deletion and targeted knock-in of a kinase inactive
mutant p110δ D910A allele (Clayton et al., 2002; Okkenhaug
et al., 2002). The latter mice were generated due to concern that
deletion of individual regulatory or catalytic subunits appears to
result in compensatory changes in expression of remaining PI3K
genes. Also, the catalytically inactive protein could still function
in a scaffolding capacity during assembly of receptor-induced sig-
naling complexes (Okkenhaug et al., 2002). p110δ−/−mice (com-
pletely deleted for p110δ) have normal peripheral T cell numbers
but impaired T-dependent antibody production (Clayton et al.,
2002). Subsequent work relying on T and B cell conditional dele-
tion of a p110δ floxed allele demonstrated that loss of p110δ
expression in T cells due to conditional deletion with Lck-Cre
is sufficient to disrupt T-dependent antibody responses despite
preserving essentially normal T cell numbers and normal T cell
proliferation in response to CD3/CD28 stimulation. This is cor-
related with an absence of AKT S473 phosphorylation in response
to stimulation with anti CD3 plus ICOS-L and significantly
decreased expression of CD40L by activated p110δ−/−− T cells
(Rolf et al., 2010). The p110δD910A/D910A mice demonstrate nor-
mal cellularity of the thymus but have about a 50% reduction in
mature T cell numbers and a decreased frequency of CD44high
effector T cells in the periphery. Phosphorylation of AKT on S473
is severely reduced after CD3 crosslinking, however T cell prolif-
eration and IL-2 secretion when stimulated with anti CD3/CD28
coated beads was the same as WT mice. This stands in contrast
to the diminished proliferation and IL-2 secretion that was seen
when p110δD910A/D910A were crossed to a TCR Tg and stimulated
with cognate peptide/APC, indicating that strength of stimula-
tion may compensate in some manner for loss of efficient PIP3
generation in such cells, perhaps via activation of p110γ as dis-
cussed below (Alcazar et al., 2007). Similar to r1T/r2n mice,
mTOR-independent TCR signaling to induce NF-κB activation
was reduced in p110δD910A/D910A T cells but NF-κB activation
normalized when CD28 costimulation was provided (Okkenhaug
et al., 2006). In summary, loss of the individual p110δ subunit
or all class IA PI3Ks results in consistent inhibition of AKT S473
phosphorylation implying decreased mTORC2 activity, but TCR-
induced proliferation may be relatively spared, depending on the
strength of the TCR stimulation. Loss of IL-2 production also
appeared to be more severe in the absence of all Class IA PI3K
expression. These effects differ from the effects of rapamycin
treatment or deletion of mTOR where proliferation is more
severely inhibited, initial IL-2 production is preserved, but recall
cytokine responses are diminished. Mechanisms underlying these
differences may relate to CD4 T cell effector differentiation and
are discussed in the next section.
There are conflicting data on the coupling of p110γ to TCR sig-
naling. In one report, T cells from p110γ−/− mice have reduced
anti CD3 and anti CD3/CD28-induced proliferation, IL-2 pro-
duction, and IFN-γ production (Sasaki et al., 2000), to some
extent resembling T cell anergy. However, while the addition of
exogenous IL-2 can rescue Th1 cell anergy induced by rapamycin
(Powell et al., 1999), supplementation of IL-2 only partially cor-
rects the defective proliferation of p110γ−/− T cells in response to
anti CD3/CD28 (Alcazar et al., 2007). Furthermore, p110γ−/− T
cells demonstrate reduced AKT S473 and mitogen activated pro-
tein kinase (MAPK) phosphorylation after stimulation with anti
CD3 or anti CD3/CD28, correlating with decreased F-actin poly-
merization and impaired formation of stable conjugates between
T cells and peptide loaded APCs (Alcazar et al., 2007). These data
stand in contrast to studies which examined early signaling events
in p110γ−/− T cells following TCR binding to cognate peptide
on APC. Recruitment of an AKT PH domain-GFP fusion protein
to the immunologic synapse following stimulation with peptide
loaded APC is normal in T cells lacking p110γ while it is impaired
in p110δD910A/D910A T cells and CD28−/− T cells (Garcon et al.,
2008). Likewise, proliferation, downregulation of CD62L, and
upregulation of CD44 in response to antigen in vivo is normal in
CD4 T cells lacking p110γ (Thomas et al., 2008). Proliferation of
CD8 T cells lacking p110γ was also normal in response to antigen
pulsed APC in vitro and vaccinia virus expressing a model antigen
in vivo (Martin et al., 2008). The mechanism underlying differ-
ences between the normal proliferation to antigen but reduced
proliferation to anti CD3/CD28 crosslinking in p110γ−/− T cells
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as compared to the reduced proliferation to antigen but near nor-
mal proliferation to anti CD3/CD28 in T cells lacking normal
p110δ remains incompletely understood, but it may be related to
increased susceptibility of p110γ−/− T cells to activation induced
cell death as p110γ−/− thymocytes showed enhanced death com-
pared to WT when exposed to anti CD3 in the presence of
adenosine receptor agonists (Sasaki et al., 2000). It will be inter-
esting to see if preservation of antigen induced mTOR activation
contributes to the proliferation seen from p110γ−/− T cells.
Deletion of PTEN in tumors is associated with constitutive
accumulation of PIP3 and appears to promote proliferation and
tumor survival, thus it was not surprising when mice with T
cell conditional deletion of PTEN were found to develop a lym-
phoproliferative disorder and die prematurely of CD4 T cell
lymphomas (Suzuki et al., 2001). Prior to the onset of lym-
phoma, peripheral T cells from such mice demonstrate enhanced
proliferation, IL-2 secretion, IFN-γ secretion, and AKT S473
phosphorylation after CD3/CD28 stimulation. T cells demon-
strate a spontaneous activated, CD69 high phenotype and are
autoreactive. Furthermore, such mice develop autoimmunity and
hypergammaglobulinemia due to aberrant self-tolerance. This
immunopathology appears strongly related to the timing of
loss of PTEN expression because conditional deletion of PTEN
after completion of thymic negative selection using OX40-Cre,
which results in deletion in mature peripheral T cells after ini-
tial activation, does not lead to development of autoreactive cells
or systemic autoimmunity despite increased lymph node cel-
lularity (Soond et al., 2012). OX40-Cre PTEN null T cells do
exhibit enhanced CD3-induced proliferation and IFN-γ produc-
tion compare toWT. Furthermore, consistent with an exaggerated
AKT/mTOR activation state, such mice develop an increased
secondary contact hypersensitivity recall response.
NAïVE CD4 T CELLS REQUIRE PI3K-INDUCED
mTOR-DEPENDENT AND mTOR-INDEPENDENT SIGNALS
Naïve CD4 T cells acquire restricted patterns of cytokine expres-
sion or regulatory function as a consequence of cytokine exposure
or strength of antigenic stimulation during the period of initial
activation. Specific patterns of cytokine expression are associated
with master transcriptional regulators in the different lineages:
Th1 cells express Tbet and IFN-γ; Th2 cells express GATA3 and
IL-4, IL-5, and IL-13; Th17 cells express ROR-γT and IL-17A/F;
Treg express FoxP3 and suppress other T cell responses [reviewed
in Weaver et al. (2006)]. More recently an additional subset
termed T follicular helper (Tfh) cell was identified that supports
generation of T-dependent antibody production and is depen-
dent on expression of the transcription factor Bcl6 and marked
by surface ICOS and CXCR5 and secretion of IL-21 [reviewed in
Crotty (2011)]. A requirement for mTOR activation in helper T
cell differentiation was initially suggested by the observation that
rapamycin inhibition of mTOR promotes de novo expression of
FoxP3 by naïve T cells and promotes expansion of Tregs in vitro
(Battaglia et al., 2005). Such rapamycin-induced FoxP3+ cells
are functional Tregs capable of suppressing pancreatic allograft
rejection in vivo. Additional evidence of a critical role for mTOR
signals in promoting effector function and inhibiting Treg gener-
ation comes from the mice with conditional deletion of mTOR in
T cells. Following initial activation, a high proportion of mTOR
deficient T cells spontaneously become inducible FoxP3+ Tregs
andTh effector differentiation to Th1, Th2, and Th17 fates in vitro
is severely impaired (Delgoffe et al., 2009).
Mice with individual T cell conditional deletion of either
mTORC1 ormTORC2 have provided surprising insight into non-
overlapping roles for each of these complexes in normal T cell
effector differentiation. Selective loss of mTORC1 following Rheb
deletion results in CD4 T cells incapable of Th1 and Th17 differ-
entiation but preserves the ability to make Th2 cells in response
to IL-4 stimulation (Delgoffe et al., 2011). More recently, T cell
conditional deletion of Raptor was shown to impair Th17 dif-
ferentiation but Th1 differentiation was preserved (Kurebayashi
et al., 2012). Conversely, deletion of Rictor with resulting loss of
mTORC2 causes loss of Th2 differentiation, with variable effects
on Th1 and Th17 differentiation depending on the timing of
Cre expression in the thymus based on the particular Cre trans-
genic line that the floxed Rictor allele is crossed to (Lee et al.,
2010; Delgoffe et al., 2011). T cell-dependent antibody produc-
tion in mice with mTORC1 deficient T cells is normal but mice
with mTORC2 deficient T cells have decreased antibody titers
in both mouse lines, although enumeration of Tfh was not per-
formed. As Th17 cells contribute significantly to the pathology
of a murine model for multiple sclerosis, experimental autoim-
mune encephalitis (EAE), the Rheb deficient T cell mice were
compared to WT in the EAE system. Rheb deficiency in T cells
results in lower EAE severity scores than WT despite all mice
developing some symptoms. This correlates with fewer T cells
infiltrating the spinal cord and a lower frequency of IL-17 and
IFN-γ secretion by T cells extracted from spinal cords of the Rheb
deficient T cell mice. Strikingly, 60% of the Rheb deficient T cell
mice immunized to induce EAE develop ataxia consistent with
“non-classical EAE” that has been observed with induction of
Th2 cells in other reports (Wensky et al., 2005). Rheb deficient
mice with ataxia have T cell infiltrates in their cerebellum that
produce Th2 cytokines in vitro in response to antigen (Delgoffe
et al., 2011). Treg number and function are normal following
T cell conditional deletion of Rheb and Rictor, but Rictor deficient
T cells that only have mTORC1 demonstrate enhanced sensi-
tivity to rapamycin in promoting expression of FoxP3 in vitro
(Delgoffe et al., 2011). The observation that prolonged incubation
of cells with higher doses of rapamycin blocks mTORC2 assembly
serves to explain both this enhanced sensitivity of Rictor deficient
T cells to rapamycin and the fact that loss of both mTORC1 and
mTORC2 by deletion of mTOR is necessary to mimic the effect of
rapamycin on promoting Tregs (Sarbassov et al., 2006).
Based on the regulation of mTOR by PI3K, the PI3K knock-
out models should recapitulate the effects of mTOR deletion
on effector differentiation. However, just as the mTORC1 and
mTORC2 deficient T cells demonstrated unexpected effector phe-
notypes, disruption of PI3K proximal signaling has also provided
surprises. T cells from the r1T/r2n mice lacking all p85 regula-
tory subunits and having low or absent p110α, β, and δ catalytic
subunit expression supported normal Th1 polarization but Th2
cultures had decreased IL-4 and increased IFN-γ. This is consis-
tent with the report above from Delgoffe et al. noting selective
loss of IL-4 expression from T cells deficient in mTORC2 and the
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relative preservation of mTORC1-dependent S6 phosphorylation
over mTORC2-dependent AKT S473 phosphorylation that Deane
et al. report in the r1T/r2n mice. However, the frequency of
CD4+CD25+FoxP3+ natural Tregs in the spleen was significantly
decreased in r1T/r2n mice despite normal thymic Treg num-
bers. This is in contrast to normal Treg numbers in the periphery
of mice with T cells lacking Rictor (Lee et al., 2010; Delgoffe et al.,
2011). T-dependent B cell responses to NP-Ova were impaired
and germinal centers following vaccination were decreased but
antiviral responses to mouse hepatitis virus were normal (Deane
et al., 2007). In addition, the mice were noted to develop sponta-
neous autoimmunity with corneal opacities and eye lesions found
to resemble Sjögren’s syndrome. On necropsy the r1T/r2n mice
were noted to have a predominantly CD4 T cell infiltrate into
lacrimal and salivary lands with lymphadenopathy, splenomegaly,
and anti-nuclear and anti SSA autoantibodies (Oak et al., 2006).
A mechanistic link between decreased Tregs and autoimmunity
was speculated upon but not formally tested in this report. These
clinical findings arise in the mice despite the biochemical pro-
file with loss of AKT S473 phosphorylation that resembles the
Rictor deficient T cell mice that lack autoimmunity. This serves
to highlight the importance of additional PI3K signaling path-
ways distinct from the AKT/mTOR axis in the maintenance and
function of Tregs.
Further characterization of the p110δD910A/D910A mice
demonstrated that Th1 and Th2 differentiation in vitro is
markedly reduced (Okkenhaug et al., 2006). Interestingly, when
in vivo Th2 differentiation was examined following immuniza-
tion with Ova/Alum, p110δD910A/D910A mice exhibit decreased
Th2 responses and inappropriate Th1 responses. That is, spleno-
cytes have decreased Ova specific IL-4, IL-5, and IL-13 secretion
but enhanced Ova specific IFN-γ and CXCL10 secretion, and
the mice demonstrate a reduction in Th2-dependent allergic
airway inflammation in vivo. This appears to be secondary to
defective IL-10 production by p110δD910A/D910A T cells because
neutralization of IL-10 in vitro during Ova stimulation enhances
WT splenocyte IFN-γ production and addition of IL-10 sup-
presses p110δD910A/D910A splenocyte IFN-γ production (Nashed
et al., 2007). Phosphorylation of mTORC1 substrates is not
described in these manuscripts to see if the phenotype is related
to imbalance of mTORC1 versus mTORC2, as is ostensibly
predicted by the Rictor conditional deletion data above.
Th17 differentiation is also partially p110δ-dependent. IL-17A
production from Th17 culture in vitro is strongly inhibited by
the p110δ isoform specific inhibitor IC87114 while IFN-γ pro-
duction in Th1 culture is only modestly decreased. Likewise,
induction of Th17 cells in p110δD910A/D910A mice in vivo in EAE is
decreased while Th1 responses are spared, resulting in less severe
clinical symptoms (Haylock-Jacobs et al., 2011). This preserva-
tion of Th1 cytokine expression resembles the phenotype noted
for the r1T/r2n mice and to some degree the Rictor T cell
deficient mice noted above (Deane et al., 2007; Delgoffe et al.,
2011).
Despite the preferential Th1 phenotype under a typical Th2
stimulus and in the EAE model above, Th1-driven contact
hypersensitivity responses in p110δD910A/D910A mice are reduced
(Soond et al., 2010). This would lead to a prediction that
such mice would have increased susceptibly to the Th1-sensitive
pathogen Leishmania major. However, while p110δD910A/D910A
mice have diminished T cell proliferation, IFN-γ, and TNF-α
production to Leishmania antigens after infection, consistent
with impaired Th1 function, the clinical outcome of infectious
challenge is actually enhanced resistance, smaller lesion size,
and more rapid parasite clearance. This was found to correlate
with impaired generation of IL-10 producing Treg and recruit-
ment of such Tregs to sites of infection in p110δD910A/D910A
mice (Liu et al., 2009). Adoptive transfer of WT Tregs to
p110δD910A/D910A mice reverses their Leishmania resistance, sup-
porting the hypothesis that Treg dysfunction permits the inef-
ficient p110δD910A/D910A Th1 response to be sufficient to clear
infection. Additional evidence for functional Treg deficiency in
the p110δD910A/D910A mice comes from their spontaneous devel-
opment of autoimmune colitis. Such mice have 50% reduction
in Treg frequency in the periphery compared to WT and no
detectable IL-10 secretion by cultured Tregs. This is associated
with reduced in vitro suppression compared to WT Tregs and
an inability of p110δD910A/D910A Tregs to suppress colitis induced
by adoptive transfer of naïve T cells into RAG1−/− mice (Patton
et al., 2006). In contrast to these autoimmune findings in mice
with proximal PI3K defects, to date, no spontaneous autoimmune
phenotype has been reported in mice with T cell conditional dis-
ruption of mTORC1, mTORC2, or both (Delgoffe et al., 2009,
2011; Lee et al., 2010).
Reminiscent of the mice with T cells lacking mTORC2 com-
plexes and the r1T/r2n mice, p110δD910A/D910A mice demon-
strate abnormal T-dependent antibody responses. Such mice are
largely devoid of germinal centers in spleen and lymph nodes
(Okkenhaug et al., 2002). This appears to be due to a require-
ment for p110δ expression in Tfh, rather than B cells, based
on subsequent conditional deletion experiments. Mice bearing
p110δ2loxP/2loxP alleles were crossed with CD4-Cre to delete p110δ
during the double positive thymocyte stage or Ox40-Cre to delete
p110δ in peripheral T cells after their initial activation. In both
types of mice, PD-1+ CXCR5+ Tfh are decreased 10-fold and
5-fold, respectively with corresponding decreases in the number
of germinal center B cells and the number of germinal centers
per follicle within lymph nodes. Mechanistically, this correlates
with decreased ICOS-induced AKT S473 phosphorylation and
reduced expression of factors critical for T cell-dependent B cell
help including CD40L, IL-21, IL-4, and c-Maf in T cells lacking
p110δ expression (Rolf et al., 2010). A detailed Tfh phenotype has
not been reported following T cell conditional deletion of Rictor,
however the data from the PI3K deficient mice would predict that
Tfh effector cytokines might be reduced.
Despite the controversy surrounding whether p110γ is cou-
pled directly to TCR or CD28, it is clear that loss of p110γ impacts
T cell effector function. Both CD4 and CD8 p110γ−/− T cells
have defective effector T cell migration in vivo that correlates with
impaired migratory responses to chemokines in vitro (Martin
et al., 2008; Thomas et al., 2008). Expression of granzyme B and
IFN-γ appears normal in p110γ−/− CD8 effector T cells gener-
ated in vivo by antigen exposure (Martin et al., 2008). Effector
differentiation of p110γ−/− CD4 T cells in vivo has not been fully
described and impaired footpad swelling induced by LCMV and
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impaired T-dependent antibody responses in p110γ−/−micemay
be related to loss of p110γ expression in cells other that CD4 T
cells (Sasaki et al., 2000). Anti CD3/CD28 induced phosphoryla-
tion of AKT S473 is decreased in p110γ−/− T cells, suggesting
that CD4 effector differentiation may be abnormal in a man-
ner analogous to mTOR or mTORC2 deficient T cells but in
light of partial functional redundancy of p110δ activity in such
cells, direct measurement of mTOR substrate phosphorylation in
response to antigen or anti CD3/CD28 will ultimately need to be
performed to address whether the p110γ−/− phenotype is mTOR
related.
In contrast to immune dysregulation associated with Treg dys-
function after reducing PI3K activity, enhancing PI3K function
by PTEN deletion in the OX40-Cre T cell conditional model
not only enhances IFN-γ production in vitro, but also results
in enhanced Th1 effector function in vivo by several measures.
PTEN deletion in T cells increases contact hypersensitivity reac-
tions. Adoptively transferred OX40-Cre PTEN floxed OT2 TCR
Tg T cells secrete more IL-2 and IFN-γ after activation by infec-
tion with attenuated Listeria expressing ovalbumin and support
better expansion of endogenous ovalbumin-specific CD8 T cells
than WT OT2 cells. In addition, adoptively transferred OX40-
Cre PTEN floxed OT2 T cells are better at rejecting syngeneic
tumor expressing ovalbumin antigen (Soond et al., 2012). These
findings are consistent with a robust Th1 response in the pres-
ence of increased PI3K/AKT/mTOR activity, but experiments to
dissect if any findings were exclusively due to enhanced mTOR
activity await experiments culturing PTEN null T cells or treat-
ing Ox40-Cre PTEN floxed mice with rapamycin or mTOR kinase
inhibitors.
A MODEL FOR PI3K/AKT/mTOR REGULATION OF T CELL
EFFECTOR FUNCTION
In an effort to propose a unifying model to explain the var-
ied phenotypes arising from blockade of the PI3K/AKT/mTOR
axis at different points, it is useful to consider experiments that
disrupt more proximal and distal signaling events in T cells.
Premature interruption of CD3/CD28 signaling or activation by
very low doses of cognate peptide in CD4 T cells promotes expres-
sion of FoxP3 that is further enhanced by exposure to PI3K
inhibitors and rapamycin (Kang et al., 2008; Sauer et al., 2008).
Through use of dose responses to selective PI3K inhibitors, Sauer
et al. attribute FoxP3 induction to inhibition of PI3Kα and δ
upstream of AKT and mTOR. These findings raise a paradox:
small molecule inhibitors of PI3K, AKT, and mTOR all result in
a similar phenotype, promoting induction of FoxP3 expression
following activation of naïve CD4 T cells, but the phenotypes of
mice with genetic lesions resulting in loss of T cell PI3K expres-
sion demonstrate inefficient Treg production and decreased Treg
function. Furthermore, mice with T cell conditional deletion of
mTOR phenocopy the small molecule inhibitors and generate
Tregs at the expense of effector helper T cells. These observa-
tions serve to highlight that there are mTOR-dependent effects
of PI3K, mediated by AKT, that are necessary to suppress FoxP3
expression and promote normal effector function and that there
are mTOR-independent effects of PI3K, some of which are nec-
essary for normal inducible Treg differentiation. This is shown
schematically in Figure 1, and details of the potential mechanisms
for this effect are discussed below.
There are several potential mechanisms, currently largely spec-
ulative, to explain how loss of PI3K enzymatic activity, with
associated decreased mTOR activity, may result in fewer and less
functional Tregs. First, PI3K-dependent accumulation of PIP3
results in localization of other families of signaling molecules
near the immunologic synapse including Vav guanine nucleotide
exchange factors for Ras related GTPases Rac and Rho that con-
trol cell motility and Tec family tyrosine kinases that mediate
PLCγ activation [reviewed in Cantrell (2001)]. A role for such
pathways in T cell activation and effector cytokine expression
is well established, but a direct connection between PI3K, Tec,
Vav, and Treg function is incompletely characterized. However,
disruption of other molecules downstream, including the Bcl-
10 and PKCθ components of the NF-κB signaling pathway distal
to the Tec family kinases, impairs generation of Tregs (Schmidt-
Supprian et al., 2004). Also, Tregs normally have elevated levels
of PTEN expression. This is associated with defective phospho-
rylation of AKT S473 in response to IL-2 stimulation in Tregs as
compared to effector T cells and with defective Treg proliferation
in response to TCR stimulation in the presence of IL-2 without
concurrent CD28 ligation (Bensinger et al., 2004). Conditional
deletion of PTEN in T cells does not affect generation of Tregs,
the amount of FoxP3 they express, or the suppressive capacity of
Tregs, but it does result in enhanced Treg proliferation in response
to IL-2 or TCR stimulation (Walsh et al., 2006). Taken together,
these data suggest that the Treg defects following loss of PI3K
expression might be due to differential sensitivity of Tregs to
decreased levels of PIP3 compared to effector cells due to high
Treg PTEN expression. Preferential inhibition of Treg prolifera-
tion and suppressor cytokine production would be predicted to
result in an enhanced ratio of effector T cells to Tregs and autoim-
munity in the PI3K deficient mice. Such hypotheses await further
experimental evaluation.
Another paradox that arises comparing T cells lacking PI3K
with those lacking mTOR is how do PI3K null cells pro-
mote some effector function if they are unable to activate
mTOR? It is important to remember that other inputs in addi-
tion to TCR and CD28-induced PI3K/AKT are able to activate
mTOR. In particular, chemokine receptors via p110γ, cellu-
lar energy stores by regulating the adenosine monophosphate-
dependent kinase (AMPK) pathway, cytoplasmic amino acids
via the Ras-related small GTPase Rag proteins, and hypoxia via
the hypoxia-induced factor protein regulated in the development
of DNA damage response 1 (REDD1)/hypoxia-induced factor
1α (HIF1α) pathway, ERK and RSK downstream of Ras, and
phosphatidic acid produced by phospholipase D are potent
regulators of mTOR activation [reviewed in Laplante and
Sabatini (2012); Waickman and Powell (2012)]. The capac-
ity of these inputs to regulate mTOR activation in T cells is
reflected by the ability of 2-deoxyglucose (2-DG) mimicking glu-
cose deprivation, 5-aminoimidazole-4-carboxamide ribonucleo-
side (AICAR) mimicking cellular energy depletion, and n-acetyl
leucine (NALA) mimicking amino acid depletion to result in
anergy when present during CD3/CD28 stimulation of T cells,
analogous to rapamycin treatment (Zheng et al., 2009). The
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FIGURE 1 | PI3K signaling results in the activation of both
mTOR-dependent and independent pathways in T cells. A schematic
representation of PI3K signaling is shown demonstrating mTOR-independent
and mTOR-dependent signaling cascades. Lines with arrows indicate
activating signals and lines with bars indicate inhibitory signals. Importantly,
this graphic does not include all of the nuanced inputs that are discussed in
the text. Rather, these pathways represent connections and not absolute
requirements for signaling. For example, while elimination of p110δ or all PI3K
regulatory subunits leads to decreased NF-κB, such a deficit can be overcome
by the addition of CD28 signaling. Overall, PI3K-induced mTOR-independent
signaling can influence both the activation and inhibition of T cells as well as
the generation and function of Tregs. The PI3K-induced mTOR-dependent
pathways can influence CD4 effector differentiation and function as well as
inhibit the generation of Tregs.
presence of normal energy, amino acids, and normoxia to pro-
mote mTOR activation is therefore consistent with the reported
preservation of some mTORC1 activity in the r1T/r2n mice
(Deane et al., 2007). This relative increase in mTORC1 activity
over mTORC2 activity in these mice supports the observed rela-
tive preservation of Th1 cytokine production over Th2 cytokines,
analogous to the Rictor deficient T cell mice noted above (Lee
et al., 2010; Delgoffe et al., 2011).
Finally, there are two mTOR-dependent pathways that can
negatively regulate FoxP3 expression whose loss may explain the
increased FoxP3 expression in mTOR null T cells. First, HIF1α
is induced by mTORC1 and has been shown to directly bind to
FoxP3 protein and promote its ubiquitination and degradation
(Dang et al., 2011). Second, the Foxo transcription factors directly
bind to and transactivate the FoxP3 promoter, and they are inacti-
vated in an mTORC2-dependent manner following phosphoryla-
tion by doubly phosphorylated activated AKT, leading to nuclear
export of the Foxos [reviewed in Coffer and Burgering (2004)].
The importance of the latter pathway to Tregs is seen following
T cell conditional deletion of Foxo1 and Foxo3. Individually they
have overlapping function in T cells to maintain naïve T cells
in quiescence, but their simultaneous deletion in T cells results
in functional Treg deficiency with early fatal autoimmunity that
can be prevented by adoptive transfer of WT Treg (Ouyang et al.,
2010). The fact that an increase in Tregs was observed following
deletion of mTOR but not in the Rheb and Rictor T cell con-
ditional knockouts suggests that loss of both of these pathways
is necessary to result in enhanced generation of FoxP3+ Tregs
(Lee et al., 2010; Delgoffe et al., 2011).
DISTAL INHIBITION OF THE PI3K/AKT/mTOR AXIS SHOULD
YIELD MORE RELIABLE BLOCKADE OF T CELL MEDIATED
PATHOLOGY
Based on the data and model above, treatment with mTOR
inhibitors for immunologic diseases would be predicted to not
only suppress immune responses but also potentially promote
tolerance by fostering anergy and the induction of Treg. For
example, in a mouse model of non-myeloablative peripheral
blood stem cell transplantation, we found that treatment with
cyclosporine led to eventual graft rejection while treatment
with rapamycin led to stable mixed chimerism, even after the
rapamycin was stopped. Such engrafted mice had negative mixed
lymphocyte reactions to both donor and recipient target cells,
indicating tolerance was achieved (Powell et al., 2005). This
preclinical data served as the basis for a trial of human transplan-
tation to treat sickle cell anemia with matched sibling donors that
specifically avoided use of standard calcineurin inhibitors for graft
versus host disease (GVHD) prophylaxis. Patients received alem-
tuzumab for T cell depletion, low dose total body irradiation, and
peripheral blood stem cell transplant with rapamycin for GVHD
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prophylaxis. Nine of ten patients engrafted with mixed donor
chimerism sufficient to abrogate symptoms of sickle cell disease,
and patients that have tapered off their immunosuppression have
demonstrated stable engraftment, consistent with donor-specific
tolerance (Hsieh et al., 2009).
In contrast to the effects of mTOR blockade, loss of PI3K
expression in T cells leads to consequences on both Treg and effec-
tor T cell function, with the net effect of enhanced or suppressed
immune responses in vivo strongly dependent on the context. A
recent study examined PI3K inhibition as a means of suppress-
ing cardiac allograft rejection (Ying et al., 2012). Transplanting
male hearts into female mice results in HY antigen driven chronic
allograft rejection that is mitigated if the hearts are transplanted
into p110δD910A/D910A female recipients. Splenocytes from both
rejecting WT and non-rejecting p110δD910A/D910A recipient mice
proliferate equally well to HY peptide, however, indicating that
the absence of rejection in p110δD910A/D910A recipients is not
due to tolerance. Instead, defective trafficking appears to pre-
vent rejection, as adoptive transfer of HY specific TCR Tg T cells
demonstrates reduced localization of the p110δD910A/D910A HY-
specific T cells into male allografts despite normal trafficking of
adoptively transferred cells to other tissues. Based on this, the
authors tested the selective PI3K p110δ inhibitor IC87114 and
found it also prevents rejection by blocking localization of allore-
active cells to the graft but fails to induce tolerance. The inability
of proximal PI3K blockade to induce transplant tolerance resem-
bles the inability of cyclosporine to promote engraftment in the
stem cell transplant model discussed above and stands in contrast
to the tolerance induced by rapamycin in that model.
Interestingly, the capacity for proximal PI3K blockade to
potentiate immune function in specific contexts may nicely syner-
gize with the broader ability of PI3K blockade inhibit tumor cell
proliferation to make PI3K inhibitors particularly well suited to
cancer treatment, reviewed in So and Fruman (2012). To this end,
mice were given subcutaneous implants of different syngeneic
tumors and then treated with immunotherapy in the presence or
absence of ZSTK474, a pan-class I PI3K inhibitor. It was found
that this drug both inhibits tumor growth and has the ability to
enhance the efficacy of immunotherapy (Marshall et al., 2012).
The authors did not assess whether impaired Treg function
contributed to tumor clearance, but they demonstrate that inhibi-
tion of PI3K is sufficient to suppress DC secretion of IL-10 while
permitting secretion of IL-12. This appears to result in enhanced
Th1 immunity since neutralization of IFN-γ in vivo by blocking
antibody abrogated the protection afforded by immunotherapy
plus ZSTK474. In this regard, we would predict that mTOR inhi-
bition in the absence of proximal PI3K blockade might also have
directs effects on inhibiting tumor growth but would serve to
limit development of anti-tumor immunity.
SUMMARY
By employing genetic analysis it has become clear that in T
cells what initially appeared to be a straightforward connection
between components of the PI3K signaling cascade via AKT to
mTOR is substantially more complex. We have only been able
to show a small subset of data published on the topic to illus-
trate this point and apologize to authors for whom we were not
able to include their work. While inhibiting PI3K and mTOR
interferes with T cell effector function, what has become clear
is that through the inhibition of distal targets in these signaling
pathways, selective effects can be achieved. For example, a drug
that blocks mTORC2 might be helpful to treat Th2-mediated
asthma without blunting Th17 and Th1-mediated antifungal and
antibacterial responses. Conversely, an mTORC1 selective drug,
unlike rapamycin that can inhibit mTORC2 under prolonged
exposure to higher doses, might be helpful in a disease like mul-
tiple sclerosis mediated by Th17 and Th1 cells but might permit
effective vaccine responses to seasonal influenza by preserving Tfh
function. As the PI3K-induced mTOR-independent pathways in
T cells become more precisely defined, blockade of nodes distal
in the pathway might avoid unintended effects that interfere with
function of Treg. Finally, it may turn out that concomitant distal
inhibition of both mTOR-dependent and independent pathways
will lead to the most robust and precise clinical outcomes.
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